IP Library › Granted Patent US 12,365,906
Granted Patent B2
US 12,365,906 · App. 18/339,197 · Granted Jul 22, 2025

Immunomodulatory fusion proteins and uses thereof

Inventors: Shannon K. Oda (Lake Forest Park, WA); Philip D. Greenberg (Mercer Island, WA); Thomas M. Schmitt (Seattle, WA)
Assignee: Fred Hutchinson Cancer Center
C12N15/62A61K39/0011A61K40/11A61K40/22A61K40/32A61K40/416A61K40/421A61K40/4243C07K14/4705C07K14/7051C07K14/70521C07K14/70578A61K2239/38A61K2239/48C07K2319/03C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,906
App. No.
18/339,197
Granted
Jul 22, 2025
Kind
B2
Abstract

The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.

Claims (65)

1. A method of treating a cancer or a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a T cell, or of a pharmaceutical composition comprising the T cell and a pharmaceutically acceptable carrier, excipient, or diluent, wherein the T cell expresses:

(1) a fusion protein comprising:

(1)(a) an extracellular component comprising i) a CD95 (Fas) ectodomain that binds to CD95L (FasL) or ii) a CD95L (FasL)-binding fragment of the CD95 (Fas) ectodomain;

(1)(b) an intracellular component comprising a CD137 (4-1BB) intracellular signaling domain or a signal-producing portion thereof; and

(1)(c) a hydrophobic component connecting the extracellular and intracellular components, wherein the hydrophobic component comprises a transmembrane domain selected from the group consisting of CD2, CD3ε, CD3δ, CD3ζ, CD25, CD27, CD28, CD40, CD79A, CD79B, CD80, CD86, CD95 (Fas), CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD152 (CTLA4), CD200R, CD223 (LAG3), CD270 (HVEM), CD272 (BTLA), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), CD279 (PD-1), CD300, CD357 (GITR), A2aR, DAP10, FcRα, FcRβ, FcRγ, Fyn, GAL9, KIR, Lck, LAT, LRP, NKG2D, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PTCH2, ROR2, Ryk, Slp76, SIRPα, pTα, TCRα, TCRβ, TIM3, TRIM, LPA5, and Zap70; and

(2) an antigen-specific T cell receptor (TCR) and/or an antigen-specific chimeric antigen receptor (CAR), wherein the antigen-specific TCR or the antigen-specific CAR specifically binds to a cancer-specific antigen, tumor-specific antigen, or tumor-associated antigen expressed by the cancer or tumor,

and wherein the T cell is CD4+ or CD8+.

2. The method of claim 1 , wherein the T cell is CD4+.

3. The method of claim 1 , wherein the antigen-specific TCR is exogenous to the T cell.

4. The method of claim 1 , wherein the antigen-specific TCR specifically binds to an HLA class I-restricted cancer or tumor antigen.

5. The method of claim 1 , wherein the expression of the fusion protein in the T cell results in at least about a 1.5-fold, 2-fold, or 3-fold increase in survival, expansion, cytotoxicity, and/or cytokine secretion by the T cell in response to the cancer-specific antigen, tumor-specific antigen, or tumor-associated antigen, as compared to a response to the antigen by a T cell substantially the same as the T cell of claim 1 , but not expressing the fusion protein.

6. The method of claim 1 , wherein the extracellular component of the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 74, and 76; the hydrophobic component of the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 27, 78, and 198; and the intracellular component of the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 36.

7. The method of claim 1 , wherein the subject is human.

8. The method of claim 1 , wherein the cancer or tumor is a hematological malignancy or a solid tumor.

9. The method of claim 8 , wherein the cancer or tumor is a hematological malignancy comprising acute myeloid leukemia (AML); or is a solid tumor selected from a tumor of the pancreas, breast, ovary, prostate, lung, colon, liver, or heart; or a melanoma, a carcinoma, a squamous cell carcinoma, or a neuroblastoma.

10. The method of claim 1 , wherein the cancer or tumor is ovarian cancer, pancreatic cancer, or AML, and the fusion protein comprises the CD95 (Fas) ectodomain that binds to CD95L (FasL).

11. The method of claim 2 , comprising administering to the subject a therapeutically effective amount of the CD4+ T cell expressing the fusion protein, or of a pharmaceutical composition comprising the CD4+ T cell and a pharmaceutically acceptable carrier, excipient, or diluent, wherein:

the extracellular component of the fusion protein comprises a binding domain that is, or has at least 95% identity to, a FasL-binding fragment of the amino acid sequence set forth in SEQ ID NO.: 72; and wherein the intracellular signaling domain of the fusion protein is, or contains at least 95% identity to, the amino acid sequence set forth in SEQ ID NO.: 36.

12. The method of claim 11 , wherein the extracellular component of the fusion protein comprises a full-length mature extracellular portion of a Fas protein.

13. The method of claim 11 , wherein:

(a) the extracellular component of the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 72;

(b) the hydrophobic component of the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 78 or 198; and

(c) the intracellular component of the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 36.

14. The method of claim 11 , wherein the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 186 or SEQ ID NO: 188.

15. The method of claim 11 , wherein the subject is human.

16. The method of claim 11 , wherein the cancer or tumor is a hematological malignancy or a solid tumor.

17. The method of claim 16 , wherein cancer or tumor is a hematological malignancy comprising acute myeloid leukemia (AML); or is a solid tumor selected from a tumor of the pancreas, breast, ovary, prostate, lung, colon, liver, or heart; or is a melanoma, a carcinoma, a squamous cell carcinoma, or a neuroblastoma.

18. A method of treating a cancer or a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a T cell, or of a pharmaceutical composition comprising the T cell and a pharmaceutically acceptable carrier, excipient, or diluent, wherein the T cell expresses:

(i) a nucleic acid molecule encoding a fusion protein that specifically binds to a target, wherein the nucleic acid molecule comprises:

(a) a nucleic acid molecule encoding an extracellular binding domain of the fusion protein, wherein the extracellular binding domain binds to the target and wherein the nucleic acid molecule is selected from the group consisting of SEQ ID NOs: 71, 73, and 75;

(b) a nucleic acid molecule encoding a hydrophobic domain of the fusion protein, wherein said nucleic acid molecule is selected from the group consisting of SEQ ID NOs.: 4, 77, and 197; and

(c) a nucleic acid molecule encoding an intracellular signaling domain of the fusion protein, wherein said nucleic acid molecule has the sequence set forth in SEQ ID NO.: 13; and wherein the hydrophobic domain connects the extracellular and intracellular domains of the fusion protein; and

(ii) a nucleic acid molecule encoding an antigen-specific T cell receptor (TCR) and/or a nucleic acid molecule encoding an antigen-specific chimeric antigen receptor (CAR), wherein the antigen-specific TCR or the antigen-specific CAR specifically binds to a cancer-specific antigen, tumor-specific antigen, or tumor-associated antigen expressed by the cancer or tumor.

19. The method of claim 18 , wherein the T cell is CD4+ or CD8+.

20. The method of claim 19 , wherein the TCR is exogenous to the T cell.

21. The method of claim 19 , wherein the antigen-specific TCR specifically binds to an HLA class I-restricted cancer or tumor antigen.

22. The method of claim 18 , wherein the fusion protein consists essentially of (a) a CD95 (Fas) ectodomain, (b) a transmembrane domain of a CD137 (4-1BB), and (c) a CD137 (4-1BB) intracellular signaling domain.

23. The method of claim 18 , wherein the subject is human.

24. The method of claim 18 , wherein the cancer or tumor is a hematological malignancy or a solid tumor.

25. The method of claim 24 , wherein the cancer or tumor is a hematological malignancy comprising acute myeloid leukemia (AML); or is a solid tumor selected from a tumor of the pancreas, breast, ovary, prostate, lung, colon, liver, or heart; or is a melanoma, a carcinoma, a squamous cell carcinoma, or a neuroblastoma.

26. The method of claim 19 , wherein the expression of the fusion protein in the T cell results in at least about a 1.5-fold, 2-fold, or 3-fold increase in survival, expansion, cytotoxicity, and/or cytokine secretion by the T cell in response to the cancer-specific antigen, tumor-specific antigen, or tumor-associated antigen as compared to a response to the antigen by a cell substantially the same as the T cell but not expressing the fusion protein.

27. The method of claim 1 , wherein treating the cancer or tumor comprises controlling or inhibiting cancer or tumor growth in the subject.

28. The method of claim 27 , wherein the tumor is a liquid tumor or a solid tumor.

29. The method of claim 28 , wherein the tumor is a solid tumor selected from a tumor of the pancreas, breast, ovary, prostate, lung, colon, liver, or heart; or a melanoma, a carcinoma, a squamous cell carcinoma, or a neuroblastoma.

30. The method of claim 27 , wherein proliferation of T cells is increased, survival of T cells is increased, and/or T cell death is reduced in the subject following administration of the T cell or the pharmaceutical composition comprising the T cell.

31. The method of claim 1 , wherein administering the therapeutically effective amount of the T cell or of the pharmaceutical composition comprising the T cell to the subject increases or enhances persistence of T cells in the subject.

32. The method of claim 31 , wherein the subject has a liquid tumor or a solid tumor.

33. The method of claim 32 , wherein the tumor is a solid tumor selected from a tumor of the pancreas, breast, ovary, prostate, lung, colon, liver, or heart; or a melanoma, a carcinoma, a squamous cell carcinoma, or a neuroblastoma.

34. The method of claim 31 , wherein proliferation of T cells is increased, survival of T cells is increased, and/or T cell death is reduced in the subject following administration of the T cell or the pharmaceutical composition comprising the T cell.

35. A method of treating a cancer or a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a T cell, or of a pharmaceutical composition comprising the T cell and a pharmaceutically acceptable carrier, excipient, or diluent, wherein the T cell comprises:

(i) a fusion protein comprising:

(i)(a) an extracellular component comprising a binding domain that specifically binds a target;

(i)(b) an intracellular component comprising an intracellular signaling domain; and

(i)(c) a hydrophobic component connecting the extracellular and intracellular components;

wherein the binding domain is, or has at least 95% identity to, an inhibitory molecule binding domain and the intracellular signaling domain is, or has at least 95% identity to, a costimulatory or stimulatory molecule binding domain;

wherein the inhibitory molecule is or comprises (i) a CD95 (Fas) ectodomain that binds to CD95L (FasL) or (ii) a CD95L (FasL)-binding fragment of (i), and the costimulatory or stimulatory molecule is or comprises an intracellular signaling domain or a signal-producing portion thereof from CD137 (4-1BB); and wherein the T cell is a CD4+ T cell or a CD8+ T cell; and

(ii) an antigen-specific T cell receptor (TCR) and/or an antigen-specific chimeric antigen receptor (CAR), wherein the antigen-specific TCR or the antigen-specific CAR specifically binds to a cancer-specific antigen, tumor-specific antigen, or tumor-associated antigen expressed by the cancer or tumor.

36. The method of claim 35 , wherein the extracellular component of the fusion protein comprises a full-length mature extracellular portion of a Fas protein.

37. The method of claim 35 , wherein the subject is human.

38. The method of claim 35 , wherein the cancer or tumor is a hematological malignancy or a solid tumor.

39. The method of claim 35 , wherein the cancer or tumor is a hematological malignancy comprising acute myeloid leukemia (AML); or is a solid tumor selected from a tumor of the pancreas, breast, ovary, prostate, lung, colon, liver, or heart; or is a melanoma, a carcinoma, a squamous cell carcinoma, or a neuroblastoma.

40. The method of claim 35 , wherein the expression of the fusion protein in the T cell results in at least about a 1.5-fold, 2-fold, or 3-fold increase in survival, expansion, cytotoxicity, and/or cytokine secretion by the T cell in response to the cancer-specific antigen, tumor-specific antigen, or tumor-associated antigen as compared to a response to the antigen by a cell substantially the same as the T cell but not expressing the fusion protein.

41. The method of claim 35 , wherein administering the therapeutically effective amount of the T cell or of the pharmaceutical composition comprising the T cell to the subject increases or enhances persistence of T cells in the subject.

42. The method of claim 41 , wherein proliferation of T cells is increased, survival of T cells is increased, and/or T cell death is reduced in the subject following administration of the T cell or the pharmaceutical composition comprising the T cell.

43. The method of claim 35 , wherein the TCR is exogenous to the T cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2025
From: ODA, SHANNON K.; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 070820/0929 →
MERGER AND CHANGE OF NAME Recorded Apr 11, 2025
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 070825/0390 →
SECURITY INTEREST Recorded Mar 4, 2025
From: AFFINI-T THERAPEUTICS, INC.
To: CATALIO NEXUS FUND III, LP
Reel/Frame 070403/0862 →
Continuity (4)
Division 16494729
Provisional Application 62629663 · Feb 12, 2018
Provisional Application 62473282 · Mar 17, 2017
Related Publication 20240218379A1 · Jul 4, 2024
References Cited (135)
US 5712149A · Roberts · 1998 [cited by applicant]
US 6083751A · Feldhaus et al. · 2000 [cited by applicant]
US 9163258B2 · Riddell et al. · 2015 [cited by applicant]
US 9987308B2 · Riddell et al. · 2018 [cited by applicant]
US 10188749B2 · Stephan et al. · 2019 [cited by applicant]
US 10350245B2 · Adair et al. · 2019 [cited by applicant]
US 11725210B2 · Oda et al. · 2023 [cited by applicant]
US 20130202622A1 · Riddell et al. · 2013 [cited by applicant]
US 20140219975A1 · June et al. · 2014 [cited by applicant]
US 20140242049A1 · Choi et al. · 2014 [cited by applicant]
US 20140314795A1 · Riddell et al. · 2014 [cited by applicant]
US 20160008399A1 · Stephan · 2016 [cited by applicant]
US 20160083449A1 · Schmitt et al. · 2016 [cited by applicant]
US 20180044404A1 · Oda et al. · 2018 [cited by applicant]
US 20180353588A1 · Boyd et al. · 2018 [cited by applicant]
US 20180369280A1 · Schmitt et al. · 2018 [cited by applicant]
US 20190046572A1 · Stephan · 2019 [cited by applicant]
US 20190054121A1 · Stephan · 2019 [cited by applicant]
US 20190111153A1 · Stephan et al. · 2019 [cited by applicant]
US 20190127435A1 · Schmitt et al. · 2019 [cited by applicant]
US 20190209671A1 · Dai et al. · 2019 [cited by applicant]
US 20210403532A1 · Oda et al. · 2021 [cited by applicant]
AU 2016226022B2 · 2020 [cited by applicant]
CN 103965361A · 2014 [cited by applicant]
CN 110330567A · 2019 [cited by applicant]
EP 3265481A1 · 2018 [cited by applicant]
WO WO2012042480A1 · 2012 [cited by applicant]
WO WO2012079000A1 · 2012 [cited by applicant]
WO WO2012138858A1 · 2012 [cited by applicant]
WO WO2013019615A2 · 2013 [cited by applicant]
WO WO2013123061A1 · 2013 [cited by applicant]
WO WO2014106839A1 · 2014 [cited by applicant]
WO WO2014172584A1 · 2014 [cited by applicant]
WO WO2016014535A1 · 2016 [cited by applicant]
WO WO2016014565A2 · 2016 [cited by applicant]
WO WO2016014576A1 · 2016 [cited by applicant]
WO WO2016024021A1 · 2016 [cited by applicant]
WO WO2016102965A1 · 2016 [cited by applicant]
WO WO2016141357A1 · 2016 [cited by applicant]
WO WO2016203048A1 · 2016 [cited by applicant]
WO WO2018170475A1 · 2018 [cited by applicant]
Tarrant et al., Toxicological Sciences 117(1), 4-16 (2010). (Year: 2010). [cited by examiner]
Cencioni et al. (Cell Death and Disease (2015) 6, e1741). (Year: 2015). [cited by examiner]
Peroumal et al. (Oncotarget, vol. 7, No. 34, pp. 54339-54359, 2016). (Year: 2016). [cited by examiner]
Suntharalingam et al., N Engl J Med 2006;355:1018-28. (Year: 2006). [cited by examiner]
Alakoskela et al., “Mechanisms for Size-Dependent Protein Segregation at Immune Synapses Assessed with Molecular Rulers,” [cited by applicant]
Anderson et al., “Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy,” Journal for Immuno Therapy of Cancer 10:e003959, 2022. (14 pages). [cited by applicant]
Anderson et al., “Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies,” [cited by applicant]
Ankri et al., “Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity,” [cited by applicant]
Arch et al., “4-1BB and Ox40 Are Members of a Tumor Necrosis Factor (TNF)-Nerve Growth Factor Receptor Subfamily That Bind TNF Receptor-Associated Factors and Activate Nuclear Factor κB,” [cited by applicant]
Bajorath, “Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface,” [cited by applicant]
Barao, “The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses,” [cited by applicant]
Brenner, “Errors in Genome Annotation,” [cited by applicant]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality,” [cited by applicant]
Chen et al., “Molecular mechanisms of T cell co-stimulation and co-inhibition,” [cited by applicant]
Cherkassky et al., “Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition,” [cited by applicant]
Cheuk et al., “Role of 4-1BB:4-1BB ligand in cancer immunotherapy,” [cited by applicant]
Coles et al., “Expression of CD200 on AML blasts directly suppresses memory T-cell function,” [cited by applicant]
Coles et al., “The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse,” [cited by applicant]
Contini et al., “In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-1 and Fas ligand,” [cited by applicant]
Dolan et al., “PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy,” [cited by applicant]
Dustin et al., “Understanding the Structure and Function of the Immunological Synapse,” [cited by applicant]
Feldhaus et al., “A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells,” [cited by applicant]
Fourcade et al., “CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1,” [cited by applicant]
Frankel et al., “Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor,” [cited by applicant]
GenBank, “ [cited by applicant]
GenBank, “ [cited by applicant]
GenBank, “Homo sapiens hepatitis A virus cellular receptor 2 (HAVCR2), mRNA,” Accession No. NM_032782.4, Sep. 23, 2018, 5 pages. [cited by applicant]
GenBank, “ [cited by applicant]
Gong et al., “Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen,” [cited by applicant]
Grassmann et al., “S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy,” [cited by applicant]
Hanada et al., “Augmenting adoptive T cell therapy through universal chimeric costimulators,” [cited by applicant]
Hatherley et al., “Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47,” [cited by applicant]
Hatherley et al., “Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution,” [cited by applicant]
Ho et al., “CD200 Is a Marker of LSC Activity in Acute Myeloid Leukemia,” [cited by applicant]
James et al., “Biophysical Mechanism of T Cell Receptor Triggering in a Reconstituted System,” [cited by applicant]
Jang et al., “Human 4-1 BB (CD137) Signals Are Mediated by TRAF2 and Activate Nuclear Factor-κB,” [cited by applicant]
Jena et al., “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor,” [cited by applicant]
Jones et al., “Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes,” [cited by applicant]
Kawalekar et al., “Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells,” [cited by applicant]
Kawasaki et al., “Cancer stem cells, CD200 and immunoevasion,” [cited by applicant]
Kawasaki et al., “Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells,” [cited by applicant]
Keir et al., “PD-1 and its ligands in tolerance and immunity,” [cited by applicant]
Kharfan-Dabaja et al., “Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors,” [cited by applicant]
Kono, “Current status of cancer immunotherapy,” [cited by applicant]
Kornmann et al., “Fas and Fas-Ligand Expression in Human Pancreatic Cancer,” [cited by applicant]
Krause et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes,” [cited by applicant]
Kuhlmann, “Unleashing T cells for adoptive immunotherapy,” https://www.fredhutch.org/en/news/spotlight/2017/12/crd_oda_blood.html, 2017 (3 pages). [cited by applicant]
Lavrik, “Regulation of Death Receptor-Induced Apoptosis Induced via CD95/Fas and Other Death Receptors,” [cited by applicant]
Lazar-Molnar et al., “The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function,” [cited by applicant]
Leccia et al., “Cytometric and Biochemical Characterization of Human Breast Cancer Cells Reveals Heterogenous Myoepithelial Phenotypes,” [cited by applicant]
Ledbetter et al., “CD28 Ligation in T-Cell Activation: Evidence for Two Signal Transduction Pathways,” [cited by applicant]
Liu et al., “Synthesis of full length recombinant chimeric receptor anti-erbB2 scFv-CD28-ζ and construction of its eukaryotic expression vector,” [cited by applicant]
Liu et al., “The role of N-glycosylation of CD200-CD200R1 interaction of classical microglial activation,” [cited by applicant]
Ma et al., “CD28 T cell costimulatory receptor function is negatively regulated by N-linked carbohydrates,” [cited by applicant]
Ma et al., “Isolation, Culture and Biological Characteristics of Tumor Stem Cells in Human Colorectal Carcinoma,” [cited by applicant]
Maeda et al., “Engineering of functional chimeric protein G-Vargula Luciferase,” [cited by applicant]
Maus et al., “Antibody-modified T cells: CARs take the front seat for hematologic malignancies,” [cited by applicant]
Milstein et al., “Nanoscale Increases in CD2-CD48-mediated Intermembrane Spacing Decrease Adhesion and Reorganize the Immunological Synapse,” [cited by applicant]
Moreaux et al., “CD200: a putative therapeutic target in cancer,” [cited by applicant]
Motz et al., “Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors,” [cited by applicant]
Oda et al., “A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia,” [cited by applicant]
Oda et al., “A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy,” [cited by applicant]
Oda et al., “Cheating Death: A Fas-41BB Immunomodulatory Fusion Protein Obviates a Death Signal to Enhance T Cell Function and Adoptive Therapy Targeting Leukemia and Solid Tumors,” Conference Program, Retrieved from ht… [cited by applicant]
Oda et al., “Cheating Death: A Fas-41BB Immunomodulatory Fusion Protein Obviates a Death Signal to Enhance T Cell Function and Adoptive Therapy Targeting Leukemia and Solid Tumors,” [cited by applicant]
Oda et al., Cancer Research, Nov. 2022, vol. 82, No. 22, Supp. Supplement. Abstract No. PR008. Meeting Info: AACR Special Conference: Pancreatic Cancer. Boston, MA, United States. Sep. 13, 2022-Sep. 16, 2022 (2 pages). [cited by applicant]
Öhlén et al., “Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen,” [cited by applicant]
Orlinick et al., “Requirement of Cysteine-rich Repeats of the Fas Receptor for Binding by the Fas Ligand,” [cited by applicant]
Pakula et al. “Genetic analysis of protein stability and function,” [cited by applicant]
Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” [cited by applicant]
Prosser et al., “Primary Human CD8+ T Cells Engineered to Express a PD1-CD28 Chimeric Receptor are Co-Stimulated through the Exploitation of Tumor Expressed PD-L1,” [cited by applicant]
Prosser et al., “Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor,” [cited by applicant]
Ramaswamy et al., “Many Checkpoints on the Road to Cell Death: Regulation of Fas-FasL Interactions and Fas Signaling in Peripheral Immune Responses,” [cited by applicant]
Rossy et al., “The integration of signaling and the spatial organization of the T cell synapse,” [cited by applicant]
Rudd et al., “CD28 and CTLA-4 coreceptor expression and signal transduction,” [cited by applicant]
Shirakabe et al., “Mechanistic insights into ectodomain shedding: susceptibility of CADM1 adhesion molecule is determined by alternative splicing and O-glycosylation,” [cited by applicant]
Siva et al., “Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200,” [cited by applicant]
Smith et al., “The challenges of genome sequence annotation or “The devil is in the details, ”” [cited by applicant]
Snauwaert et al., “Can immunotherapy specifically target acute myeloid leukemic stem cells?” [cited by applicant]
Soto et al., “MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild type TCR,” [cited by applicant]
Starling et al., “Analysis of the Ligand Binding Site in Fas (CD95) by Site-Directed Mutagenesis and Comparison with TNFR and CD40,” [cited by applicant]
Starling et al., “Identification of Amino Acid Residues Important for Ligand Binding to Fas,” [cited by applicant]
Stromnes et al., “Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice,” [cited by applicant]
Stromnes et al., “Re-adapting T cells for cancer therapy: from mouse models to clinical trials,” [cited by applicant]
Stromnes et al., “T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma,” [cited by applicant]
Stumpfova et al., “The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma,” [cited by applicant]
Subramanian et al., “Species- and cell type-specific interactions between CD47 and human SIRPα,” [cited by applicant]
Takata-Tomokuni et al., “Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis,” [cited by applicant]
Tang et al., “The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1+ cancer therapy,” [cited by applicant]
Teague et al., “Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors,” [cited by applicant]
Tonks et al., “CD200 as a prognostic factor in acute myeloid leukaemia,” [cited by applicant]
Van den Borne et al. “The CD200-CD200 Receptor Inhibitory Axis Controls Arteriogenesis and Local T Lymphocyte Influx,” PLOS One 9(6):e98820, 2014 (10 pages). [cited by applicant]
Walton et al., “CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma,” [cited by applicant]
Willingham et al., “The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors,” [cited by applicant]
Yamao et al., “Mouse and Human SHPS-1: Molecular Cloning of cDNAs and Chromosomal Localization of Genes,” [cited by applicant]